Cannabinoid treatment for autism: a proof-of-concept randomized trial

Table 4 Impact of cannabinoid treatment, as reflected by change from baseline to end of treatment period 1 in total scores of HSQ-ASD, SRS-2, and APSI

	Median (range) [n]			Pairwise P
Assessment	Whole-plant extract	Pure cannabinoids	Placebo	Whole-plant versus placebo	Pure C. versus placebo	Whole-plant versus pure C
HSQ-ASD	− 1.1 (− 3.8 to 1.6) [40]	− 0.7 (− 4.4 to 3.8) [42]	− 0.5 (− 3.7 to 2.5) [39]	0.575	0.915	0.508
SRS-2	− 14.9 (− 45 to 15) [34]	− 8.2 (− 69 to 45) [28]	− 3.6 (− 63 to 35) [36]	0.009	0.801	0.202
APSI	− 5.4 (− 39 to 13) [38]	− 4.9 (− 19 to 22) [42]	− 1.5 (− 26 to 20) [42]	0.502	0.513	0.991

HSQ Home Situations Questionnaire–ASD; SRS-2 Social Responsiveness Scale-2nd edition; APSI Autism Parenting Stress Index
Median tests were used, as distributions were non-normal
P-values are based on Mood’s Median Test of each pairwise comparison

ISSN: 2040-2392